Penpulimab plus RMA for newly diagnosed brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests whether penpulimab with RMA can treat primary central nervous system lymphoma (PCNSL), a lymphoma that starts in the brain/eyes. It may help shrink tumors and improve outcomes, but you must meet several key eligibility rules and avoid certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with primary central nervous system lymphoma confirmed by biopsy tissue
- Your brain MRI in the last 28 days shows at least one measurable lesion, or your spinal fluid/eye exam confirms disease in the retina or vitreous
- Your daily function score is ECOG 0 to 4 (meaning you can do normal activities at a certain level)
- The lymphoma must be only in the brain/central nervous system, not in other organs or lymph nodes
- You have not had certain past immune-checkpoint treatments (anti–PD-1/PD-L1/PD-L2, CTLA-4) or CAR T therapy
- You don’t have certain serious allergies, uncontrolled infections needing treatment, or other major issues that could affect safety or results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment combinations for newly diagnosed primary CNS lymphoma (PCNSL), a rare type of brain lymphoma. It tests whether adding a drug called PD-1 (a type of immunotherapy that helps your immune system fight cancer) to the standard chemotherapy (R-MA) improves outcomes compared to R-MA alone. Participating gives access to a novel combination that may be more effective, though it involves extra monitoring and possible immune-related side effects.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.